News | November 14, 2022
Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
The dividend cheque of Rs. 9.93 crore for the Ministry of Ayush was handed over to Sonowal
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi
Subscribe To Our Newsletter & Stay Updated
